Compare Abeona Therapeutics Inc (ABEO) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Booking Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Booking Holdings Inc trades at $210.4 (market cap $159.95B). The key difference: Booking Holdings Inc is far larger — about 379.8× Abeona Therapeutics Inc's market cap, and Booking Holdings Inc pays a 0.79% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BKNG | |
|---|---|---|
Market Cap | $421.19M | $159.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $228.83 |
52-Week Low | $4.17 | $154.13 |
Enterprise Value | $276.10M | $163.43B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Booking Holdings (BKNG) trades at $209.92, down 1.39% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates with $2.54 versus $2.43 expected, and maintains robust profitability with a 25.53% net income margin. Revenue growth continues, reaching $26.92B in 2025, supported by resilient travel demand.
The outlook remains positive with a consensus price target of $239.31, implying 14% upside, though risks include geopolitical volatility and rising debt levels. Analyst sentiment is strongly bullish with 64% buy ratings, while institutional interest is growing, as seen in recent filings. Earnings momentum and free cash flow generation support the investment case, but investors should monitor debt-to-asset trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
